BOSTON, Feb. 11 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company has posted its financials through the first nine months of 2008 on Pinksheets.com for the period ending September 30, 2008. Revenues generated through the nine-months of 2008 amounted to $304,559, compared with Revenues of $331,010 for all of 2007. The Company substantially lowered its General and Administrative expense by posting $277,387 for the first nine months of 2008 compared to $650,498 for all of 2007.
The Company’s total asset base sits just below $4,000,000, as stated in the recently released financial report.
“Solos Endoscopy continues to reflect a great improvement in revenues and ability to reduce operating cost throughout last year. We believe that when the full 2008 Financials are posted, that they will show that we took a big step forward in meeting our goals of profitability and increase in shareholder value. So far, even with the current state of the economy, 2009 looks like we can continue our growth in sales and be able to achieve profitability,” stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos’ sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company’s website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.
CONTACT: Investor Relations for Solos Endoscopy, Inc., +1-866-THE-APPL(E)
Web site: http://www.solosendoscopy.com/
